Evidence map›Paper›PMID 28473624›Full record

ArticleHaematologica2017

p.Y317H is a new

Laura Eder-Azanza, Cristina Hurtado, David Navarro-Herrera, Paula Aranaz, Francisco J Novo, José L Vizmanos

Open access · goldAbstract readLetter
In one paragraph

Article in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Frontiers in cell and developmental biology · 2022
    Review
  3. Identification of aHemaSphere · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Laura Eder-AzanzaUniversity of Navarra, School of Sciences. Department of Biochemistry & Genetics, Pamplona.
Cristina HurtadoUniversity of Navarra, School of Sciences. Department of Biochemistry & Genetics, Pamplona.
David Navarro-HerreraUniversity of Navarra, School of Sciences. Department of Biochemistry & Genetics, Pamplona.
Paula AranazUniversity of Navarra, School of Sciences. Department of Biochemistry & Genetics, Pamplona.
Francisco J NovoUniversity of Navarra, School of Sciences. Department of Biochemistry & Genetics, Pamplona.
José L VizmanosUniversity of Navarra, School of Sciences. Department of Biochemistry & Genetics, Pamplona jlvizmanos@unav.es.
Universidad de Navarra · ESNavarre Institute of Health Research · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Gain of Function MutationCalreticulinCell LineFERM DomainsHumansJanus Kinase 2Primary MyelofibrosisSignal TransductionCalreticulinJAK2 protein, humanJanus Kinase 2

Identifiers

PMID28473624
PMCPMC5541889
OpenAlexW2611007532

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.